The primary outcome was 5-year LT survival benefit, defined as the difference in survival with and without LT.<h4>Results</h4>C-MELD 3.0, serum AFP, and tumor burden score (TBS) were the strongest predictors of LT survival benefit. This evidence concerns the gene AFP and neoplasm.